Bruton Tyrosine Kinase (BTK) inhibitor
Showing 1 - 25 of 9,658
Waldenstrom Macroglobulinemia Trial in China (Ibrutinib)
Active, not recruiting
- Waldenstrom Macroglobulinemia
-
Changchun, China
- +5 more
Jan 27, 2023
Waldenstrom Macroglobulinemia Trial in Japan (Ibrutinib, Rituximab)
Active, not recruiting
- Waldenstrom Macroglobulinemia
-
Chiba, Japan
- +8 more
Jan 27, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome Trial in Italy, United Kingdom, United States
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +3 more
-
Boston, Massachusetts
- +11 more
Nov 23, 2022
Hepatitis, Safety and Tolerability Trial run by the NHLBI (HEPLISAV-B)
Completed
- Hepatitis
- Safety and Tolerability
- HEPLISAV-B
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 13, 2022
Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL) Trial run by the NHLBI
Active, not recruiting
- Safety and Tolerability
- +3 more
- Zoster Vaccine Recombinant, Adjuvanted
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 10, 2022
Mantle Cell Lymphoma Trial in Hackensack (Lenalidomide, Ibrutinib, Rituximab)
Active, not recruiting
- Mantle Cell Lymphoma
- Lenalidomide
- +2 more
-
Hackensack, New JerseyThe Cancer Center at Hackensack University Medical Center
May 3, 2022
Waldenström's Macroglobulinemia (WM) Trial in China (Zanubrutinib)
Completed
- Waldenström's Macroglobulinemia (WM)
-
Beijing, Beijing, China
- +10 more
Mar 7, 2022
MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,
Active, not recruiting
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +9 more
- BTK inhibitor PCI-32765
- +5 more
-
Columbus, OhioOhio State University Medical Center
Jun 27, 2022
Diffuse Large B-cell Lymphoma Trial in China (Zanubrutinib)
Completed
- Diffuse Large B-cell Lymphoma
-
Beijing, Beijing, China
- +10 more
Oct 11, 2021
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Acalabrutinib, Obinutuzumab)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- Obinutuzumab
-
Houston, TexasM D Anderson Cancer Center
Jul 14, 2022
Atrial Fibrillation, Supraventricular Arrhythmia, Ventricular Arrhythmias and Cardiac Arrest Trial in New Hyde Park (Medtronic
Recruiting
- Atrial Fibrillation
- +4 more
- Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)
-
New Hyde Park, New YorkNorthwell (Northshore University/Long Island Jewish Hospitals)
Dec 1, 2022
Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib, Ublituximab, Umbralisib)
Suspended
- Mantle Cell Lymphoma
- Acalabrutinib
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 7, 2022
Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Worldwide
Completed
- Leukemia, Lymphocytic, Chronic, B-Cell
- +2 more
- Tafasitamab
- +2 more
-
Jacksonville, Florida
- +16 more
Dec 10, 2021
Multiple Sclerosis Trial run by the National Institute of Neurological Disorders and Stroke (NINDS) (tolebrutinib 60mg,
Active, not recruiting
- Multiple Sclerosis
- tolebrutinib 60mg
- tolebrutinib 120mg
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Relapsed/Refractory DLBCL Trial in China (Zanubrutinib, Lenalidomide)
Recruiting
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
-
Beijing, Beijing, China
- +9 more
Aug 11, 2021
Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma Trial in China (Zanubrutinib)
Completed
- Refractory Mantle Cell Lymphoma
- Relapsed Mantle Cell Lymphoma
-
Beijing, Beijing, China
- +13 more
Oct 8, 2021
Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Columbus, Salt
Active, not recruiting
- Prolymphocytic Leukemia
- +4 more
- Selinexor
- +3 more
-
Columbus, Ohio
- +1 more
Apr 29, 2022
Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma Trial in China
Completed
- Relapsed or Refractory Chronic Lymphocytic Leukemia
- Relapsed or Refractory Small Lymphocytic Lymphoma
-
Beijing, Beijing, China
- +15 more
Sep 29, 2021
Mantle Cell Lymphoma Trial in Worldwide (Bendamustine, Rituximab, Ibrutinib)
Active, not recruiting
- Mantle Cell Lymphoma
- Bendamustine
- +3 more
-
Tucson, Arizona
- +201 more
Jan 27, 2023
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Australia, Poland (TG-1701, Umbralisib, Ublituximab)
Active, not recruiting
- Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- TG-1701
- +2 more
-
East Melbourne, Victoria, Australia
- +7 more
Jan 20, 2023